Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
Pulmonary adenocarcinoma metastatic to the gingiva
Authors
M. Kadokura
Shigeru Yamamoto
Daisuke Kataoka
Makoto Nonaka
Noboru Tanio
Toshiaki Kunimura
Miki Kushima
Tamio Kushihashi
Tadanori Kawada
Toshihiro Takaba
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 4/1999
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s101470050064

Other articles of this Issue 4/1999

International Journal of Clinical Oncology 4/1999 Go to the issue

ORIGINAL ARTICLE

Development of an irradiation method of intraoperative radiation therapy for curatively resected rectal cancer

OriginalPaper

Mediastinal yolk sac tumor in a woman

CASE REPORT

Severe 5-fluorouracil-induced toxicity due to decreased dihydropyrimidine dehydrogenase activity: report of a patient survival and urinary pyrimidine and dihydropyrimidine levels

OriginalPaper

Risk factors for local recurrence after breast-conserving therapy

REVIEW ARTICLE

Reconstructive plastic surgery in cancer treatment: surgery for quality of life

OriginalPaper

Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits